1,143 results on '"T cells -- Health aspects"'
Search Results
2. HIV epidemic: From the origin towards the end
3. Tevogen reports TVGN 489 retains activity against FLiRT strains of SARS-CoV-2
4. Dassault SystAmes and CDR-Life partner to boost cancer therapy innovation
5. TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic
6. Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
7. Anocca Presents Data at ESMO Congress on Preclinical Development of its TCR-T Cell Therapies for Cancer
8. Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
9. FDA official: The risk of secondary cancer from CAR-T therapy, pioneered at Penn, is less than feared
10. Technology for In Vivo CAR T-cell Therapy Advances: In vivo CAR-T gene therapies could overcome the challenges faced by autologous and allogeneic treatments
11. TC BioPharm agrees research planning collaboration to develop Monkeypox treatment
12. Adaptin Bio Updates on FDA Clearance of IND Application for APTN-101 in Glioblastoma
13. Early antiviral CD4 and CD8 T cell responses and antibodies are associated with upper respiratory tract clearance of SARS-CoV-2 (Updated August 19, 2024)
14. PD-L1 mediated T cell inhibition by regulatory plasma cells induced after sepsis and COVID-19
15. Initial antigen encounter determines robust T-cell immunity against SARS-CoV-2 BA.2.86 variant three years later
16. The other, smaller (cell) lung cancer: Small cell lung cancer is a less common form of lung cancer and very aggressive. Researchers and drug developers are looking for treatments, especially for patients whose cancers have stopped responding to other treatments. Tarlatamab, a bispecific T-cell engager, looks promising as a third-line treatment
17. Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia
18. T-MAXIMUM PHARMACEUTICAL Announces Latest Clinical Advances in Allogeneic CAR-T Cell Therapy Breakthrough for Solid Tumors
19. Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
20. Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy
21. Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel[R]) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
22. Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23. Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
24. Chronic virus found in long COVID gut up to 2 years post-infection
25. SCG Cell Therapy Announces FDA IND Clearance of SCG142, a next-generation HPV-specific TCR T cell therapy for patients with HPV-associated solid tumors
26. Atara Biotherapeutics' Ebvallo[TM] (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
27. GC Cell Signs an MOU with PT Bifarma Adiluhung, an affiliate of KALBE group
28. Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
29. iCell Presents Positive New Follow-up Clinical Data Confirming BCMA CD19 cCAR Safely Delivers Long-term Medication Free Complete Remission from Systemic Lupus Erythematosus & Lupus Nephritis at EULAR 2024
30. Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
31. Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL(TM) Congress 2024
32. Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
33. Challenges of Expanding CAR-T Cell Therapy into Solid Tumors: The development of CAR-T therapies for solid tumor cancers presents a myriad of challenges
34. Kite and Epic Bio announce collaboration to develop new therapies for cancer
35. Data on Cancer Detailed by Researchers at University of Pennsylvania (Enhancing Cellular Immunotherapies In Cancer By Engineering Selective Therapeutic Resistance)
36. The presenting HLA determines fidelity of SARS-CoV-2 spike protein epitope prediction
37. New Findings in COVID-19 Described from La Jolla Institute for Immunology (Sars-cov-2 Breakthrough Infections Enhance T Cell Response Magnitude, Breadth, and Epitope Repertoire)
38. New Findings from National Institute of Allergy and Infectious Diseases (NIAID) in the Area of COVID-19 Reported (Il-10 Suppresses T Cell Expansion While Promoting Tissue-resident Memory Cell Formation During Sars-cov-2 Infection In Rhesus ...)
39. Differential action modes of Neutrophil Extracellular Trap-targeted drugs define T cell responses in SARS-CoV-2 infection
40. Data from Thomas Jefferson University Advance Knowledge in COVID-19 (Mrna-lnp Vaccine-induced Cd8+t Cells Protect Mice From Lethal Sars-cov-2 Infection In the Absence of Specific Antibodies)
41. Early antiviral CD4 and CD8 T cell responses and antibodies are associated with upper respiratory tract clearance of SARS-CoV-2 (Updated June 10, 2024)
42. New Findings on COVID-19 from Michigan State University Summarized (Inducing Long Lasting B Cell and T Cell Immunity Against Multiple Variants of Sars-cov-2 Through Mutant Bacteriophage Qb-receptor Binding Domain Conjugate)
43. How COVID-19 'breakthrough' infections alter your immune cells
44. Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
45. Atara Biotherapeutics Submits Tabelecleucel (Tab-cel[R]) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
46. Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
47. Valley Children's Receives Historic $15 Million Gift to Create Advanced Cell Therapy Program for Pediatric Cancer
48. RootPath Announces Publication Demonstrating How Its Novel Gene Synthesis Technology Empowers Cell Therapy in Solid Tumor Cancers
49. Tevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
50. INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.